Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Addition of JSP191 to Non-myeloablative HSCT For SCD and Beta-Thalassemia
NCT05357482Phase 2Active, not recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- May 2022
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of briquilimab in sickle cell anemia (SCA), beta thalassemia, sponsored by National Heart, Lung, and Blood Institute. Started May 2022; status: active, not recruiting.
02
Drugs
briquilimab
03
Conditions
sickle cell anemia (SCA)beta thalassemia
Beyond the preview
Go deeper on NCT05357482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05357482.